FETAL RISK, HEMATOLOGIC TOXICITY, and DEEP VEIN THOMBOSIS AND PULMONARY EMBOLISM
See full prescribing information for complete boxed warning.
- TRADE NAME: Revlimid (Celgene)
- INDICATIONS: Transfusion-dependent anemia due to myeloplastic syndromes, multiple myeloma (in combination with dexamethasone)
- CLASS: Biologic, Immunomodulator, Thalidomide analog
- HALF-LIFE: 3–5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Anakinra, Canakinumab, Certolizumab, Denosumab, Dexamethasone, Digoxin, Erythropoietin stimulating agents, Estrogen containing therapies, Leflunomide, Natalizumab, Pimecrolimus, Rilonacept, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lenalidomide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/05/2024
